#RNATX
LightNews LightNews
rti-umasschan.bsky.social
ICYMI: 📰 RTI Messenger, Issue 61
➰️ Keeping you in the loop ➰️

buff.ly/pmyzMkG

#RTImessenger #RNATx @umasschan.bsky.app
November 3, 2026
RTI Messenger Newsletter
buff.ly
November 3, 2026 at 5:01 PM
swissinitiativerna.bsky.social
Welcome Microsynth – The Swiss DNA Company – as our first Booth Sponsor for RNATX 2027!

Join us on 28 January 2027 in Bern.

Register: www.conftool.net/chrnat2027
More info: rnatx.ch

#RNATX #RNATherapeutics
October 5, 2026 at 12:02 PM
swissinitiativerna.bsky.social
Meet three confirmed speakers for RNATX 2027: Daniel Blessing (HAYA Therapeutics, keynote), Christian Berk (E.Blum & Co AG) and Felix Gnerlich (Ribocure Pharmaceutical AB).

Join us in Bern on 28 January 2027.

Register: www.conftool.net/chrnat2027

More info: rnatx.ch

#RNATX #RNAResearch
September 30, 2026 at 7:52 AM
swissinitiativerna.bsky.social
Registration is now open for the 4th Swiss RNA Therapeutics Summit!

Join researchers, clinicians and industry partners in Bern on 28 January 2027 for a full day dedicated to RNA therapeutics.

Register: www.conftool.net/chrnat2027

#RNATX #RNAResearch
September 18, 2026 at 12:55 PM
rti-umasschan.bsky.social
Congrats to the Awardees of the 2026 Michael R. Green, MD, PhD, Award in Graduate Research, Andrew Petti (RTI; Wen Xue's Lab) and Brennon Berard (MCCB; Dohoon Kim's Lab). Save the Date for their research presentations: Tuesday Sept 8, 2026 at 11:00am DiMare Center, N1-1500
#generegulation #RNATx
August 25, 2026 at 9:47 PM
scope-umasschan.bsky.social
#RNATx Advanced Imaging and Spatial ‘Omics Methods Workshop was a hit!!! Thank you @rti-umasschan.bsky.social for inviting us to host a workshop, the sponsors, and speakers for making this a reality. #advancedimaging #spatialomics #microscopy #Thankyou @umasschan.bsky.social
June 24, 2026 at 4:28 PM
scope-umasschan.bsky.social
New Special Event for @umasschan.bsky.social. Special session added due to the popular demand at RNATx 2026 for UMass Chan. Lunch provided, registration required: lp.constantcontactpages.com/ev/reg/9etjk...
Promotional flyer for a special UMass Chan event titled “Spatial Omics & Advanced Imaging: Complementary Approaches for Understanding Biology in Context.” The background is a colorful fluorescence microscopy image showing cells and neural-like structures in red, green, and blue. A note in the upper left reads, “New Special Event Added for UMass Chan!” The center section highlights two featured speakers with portraits. Tara Delorme, PhD, of UMass Chan Medical School will present research on characterizing the suprachiasmatic nucleus across species in postmortem human and non-human primate brain using MERSCOPE. Abigail Lytton-Jean, PhD, of the Koch Institute at MIT will present ToCLEM, a method combining fluorescent RNA FISH and protein labeling with sub-cellular ultrastructure by electron microscopy. Text on the right states: “Due to popular demand as a workshop at RNATx 2026, SCOPE is opening this special session for the UMass Chan community.” Additional text notes that lunch is provided and registration is required. A QR code for registration appears in the lower right corner.
June 16, 2026 at 8:03 PM
scope-umasschan.bsky.social
Promotional event flyer with a colorful fluorescence microscopy background showing purple and green cell-like structures on a dark field. Large text reads: “Join us — June 24, 2026, 10–11:30 am, UMass Chan Medical School.” The main title is “Advanced Imaging and Spatial ‘Omics Methods,” labeled as a SCOPE Imaging Applications and Technology Workshop. The event is part of RNATx, “RNA Therapeutics From Concept to Clinic,” taking place June 24–26, 2026. A QR code labeled “Event Registration” appears on the right. At the bottom are two keynote speaker headshots: Xiaowei Zhuang of Harvard University, Frederic S. Fay Awardee, and John Maraganore of JMM Innovations and founding CEO of Alnylam. Image credit: Boulting Lab.
March 5, 2026 at 10:17 PM
rnaconnect.bsky.social
RNA hydrolysis at elevated RT temps isn't a footnote. It's actively degrading your long transcripts during the reaction. New data at #RNATx '26 quantifies how much and shows what changes with an RT at 30°C.

3 modalities: SR, PacBio LR, and ONT DRS. The gains for transcripts ≥10kb are substantial.
RNAConnect to present scientific poster at RNATx 2026.
June 18, 2026 at 2:54 PM
cmordstein.bsky.social
Chemical mods on RNA (whether transient or stable) are the way to go in #RNAtx
September 6, 2025 at 11:25 AM
cmordstein.bsky.social
My search for a high range #RNA ladder (up to ~11kb) is turning out more tricky than anticipated. The only one I could find is from a supplier that is not too straight forward to order from. Any pointers to suitable products that I may have missed would be greatly appreciated! #RNAsky #RNAtx
July 30, 2025 at 8:25 AM
cmordstein.bsky.social
En route to #Edinburgh for the week! 🏴󠁧󠁢󠁳󠁣󠁴󠁿
Looking forward to catching up with friends and former colleagues at #MRC_HGU #IGC and across #EdinburghUni 😀 If you are based in Edinburgh and interested in tapping into the #RNAtx space, give me shout! #RNAsky #RNAbiology
July 6, 2025 at 10:27 AM
cmordstein.bsky.social
#RNAsky #RNAtx
April 13, 2025 at 6:36 PM
cmordstein.bsky.social
Great thread! #RNAtx
enirenberg.bsky.social Edward Nirenberg @enirenberg.bsky.social · Jan 12
Here's a clever new study looking at where mRNA vaccine lipid nanoparticles (mRNA-LNPs) go after vaccination (using relevant doses of vaccine) in non-human primates (and mice): www.cell.com/molecular-th...

Brief thread🧵
Graphical abstract showing Indian rhesus macaque with radiolabeled lipid nanoparticles injected into the right deltoid and major lymphatic organization of the macaque therein.
January 14, 2025 at 7:14 PM
cmordstein.bsky.social
Interesting - putting this on my to-read pile.
#RNAsky #RNAtx

www.biorxiv.org/content/10.1...
A generative framework for enhanced cell-type specificity in rationally designed mRNAs
mRNA delivery offers new opportunities for disease treatment by directing cells to produce therapeutic proteins. However, designing highly stable mRNAs with programmable cell type-specificity remains ...
www.biorxiv.org
January 2, 2025 at 4:54 PM
cmordstein.bsky.social
#RNAsky #RNAtx
sethcheetham.bsky.social Seth Cheetham @sethcheetham.bsky.social · Nov 18
The greatest challenge for #mRNA-LNP therapies is targeting non-liver tissues. To overcome this, we developed customisable bispecific antibodies to tether mRNA-LNPs to cell-surface proteins, achieving efficient and selective mRNA delivery in vivo. Preprint 👇

t.co/0nJj8eVsqC
November 19, 2024 at 6:07 AM
rti-umasschan.bsky.social
New siRNA therapy led by Claudio Punzo, Anastasia Khvorova, & Julia Alterman has potential to halt vision loss in age-related macular degeneration (AMD) buff.ly/EfogUGc

@UMassChan.bksy.social #siRNATx #RNATx #RNAmedicine #science #AMD
May 28, 2026 at 2:30 PM
rti-umasschan.bsky.social
RTI's @ErikSontheimer.bsky.social and Wen @XueUMass.bsky.social develop gene editing technology capable of rewriting entire chapters of the genome
buff.ly/58PLC0X #primeassembly #RNATx #CRISPR
@hycheng.bsky.social
UMass Chan scientists develop gene editing technology capable of rewriting entire chapters of the genome
Erik Sontheimer, PhD, and Wen Xue, PhD, have developed a gene editing technology that allows for precise, efficient insertion of very large DNA segments into the human genome.
buff.ly
May 14, 2026 at 1:31 PM
rti-umasschan.bsky.social
ICYMI: 📰 RTI Messenger, Issue 58
➰️ Keeping you in the loop ➰️
buff.ly/6ediNBb
#RTImessenger #RNATx @umasschan.bsky.social
Jun 24-26, 2026
Jun 24-26, 2026
buff.ly
May 13, 2026 at 4:00 PM
rti-umasschan.bsky.social
ICYMI: 📰 RTI Messenger, Issue 57
➰️ Keeping you in the loop ➰️

buff.ly/4W0Rvvs

#RTImessenger #RNATx @umasschan.bsky.app
April 15, 2026 at 4:01 PM
rti-umasschan.bsky.social
ICYMI: 📰 RTI Messenger, Issue 56
➰️ Keeping you in the loop ➰️
buff.ly/ZbSGJ1c

#RTImessenger #RNATx @umasschan.bsky.social
March 11, 2026 at 3:14 PM
rti-umasschan.bsky.social
RTI @UMassChan scientists have received a $6M+ grant to evaluate gene editing technologies for treating frontotemporal dementia: direc.to/nE19
#FTD #RNATx
@eriksontheimer.bsky.social
@umasschan.bsky.social
@jwattsgroup.bsky.social
UMass Chan Medical School scientists to assess gene editing technologies for treating frontotemporal dementia
UMass Chan scientists have received funding to explore gene editing technologies for treating frontotemporal dementia.
www.umassmed.edu
November 14, 2025 at 3:39 PM
rti-umasschan.bsky.social
TODAY is the last day to submit your abstract for a poster at the 2025 RNA Therapeutics: From Concept to Clinic (in person and virtual!) @UMassChan.bsky.social buff.ly/4hJHLdC #RNATx2025
2025 RNATx Symposium Abstracts
Abstract should provide an overview of the research topic, question, methods, results, and significance
buff.ly
March 14, 2025 at 5:30 PM
rti-umasschan.bsky.social
Less than one week left to submit your abstract for a poster at the 2025 RNA Therapeutics: From Concept to Clinic (in person and virtual!) @UMassChan buff.ly/4hJHLdC #RNATx2025
2025 RNATx Symposium Abstracts
Abstract should provide an overview of the research topic, question, methods, results, and significance
buff.ly
March 10, 2025 at 1:47 PM
shihcheng.bsky.social
Exploring RNA therapeutics for cancer, lncRNAs regulate oncogenic networks with unique potential and challenges. PMID:38424237, Nat Rev Genet 2024, @NatureRevGenet https://doi.org/10.1038/s41576-024-00693-2 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Targeting and engineering long non-coding RNAs for cancer therapy | Nature Reviews Genetics
RNA therapeutics (RNATx) aim to treat diseases, including cancer, by targeting or employing RNA molecules for therapeutic purposes. Amongst the most promising targets are long non-coding RNAs (lncRNAs), which regulate oncogenic molecular networks in a cell type-restricted manner. lncRNAs are distinct from protein-coding genes in important ways that increase their therapeutic potential yet also present hurdles to conventional clinical development. Advances in genome editing, oligonucleotide chemistry, multi-omics and RNA engineering are paving the way for efficient and cost-effective lncRNA-focused drug discovery pipelines. In this Review, we present the emerging field of lncRNA therapeutics for oncology, with emphasis on the unique strengths and challenges of lncRNAs within the broader RNATx framework. We outline the necessary steps for lncRNA therapeutics to deliver effective, durable, tolerable and personalized treatments for cancer. Therapeutics that target long non-coding RNAs (lnc
doi.org
April 30, 2025 at 6:50 AM